- Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma
- Evogene Reports First Quarter 2024 Financial Results
- Casterra Announces Additional Agreements with Seed Producers to Meet Existing & Growing Demand for its Elite Castor Seeds
- Evogene Schedules First Quarter 2024 Financial Results Release
- Biomica to Present at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
- Biomica to Present at Digestive Disease Week (DDW) Conference 2024 Annual Meeting
- Evogene and The Kitchen FoodTech Hub by Strauss Group Established Finally Foods Ltd. - Revolutionizing Protein Production in Plants for the Food Industry
- Evogene Announces Filing of Annual Report on Form 20-F
- Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification
- Bayer AG and Lavie Bio Continue for Second Year of Biofungicides Validation Following Successful Lab and Greenhouse Testing
More ▼
Key statistics
On Friday, Evogene Ltd (EVGN:NAQ) closed at 0.6949, 54.35% above the 52 week low of 0.4502 set on Oct 24, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.68 |
---|---|
High | 0.75 |
Low | 0.68 |
Bid | -- |
Offer | -- |
Previous close | 0.6949 |
Average volume | 61.66k |
---|---|
Shares outstanding | 50.58m |
Free float | 49.75m |
P/E (TTM) | -- |
Market cap | 35.46m USD |
EPS (TTM) | -0.4567 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 20:38 BST.
More ▼